1 month Zacks Research Issues Positive Forecast for SRPT EarningsMarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Equities researchers at Zacks Research raised their Q2 2026 earnings per share estimates for Sarepta Therapeutics in a report issued on Monday, October 21st. Zacks Research analyst S. Ganoria …
Earnings · Nasdaq 100 · Science
X